D Warren

580 citations

12 papers · 364 indexed · h-index 7

Impact in

Oncology top 10%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Neutropenia and Cancer Infections
Hematology top 10%
- Hematopoietic Stem Cell Transplantation

Papers in ⓘ

Hematology 6
- Chronic Myeloid Leukemia Treatments 2
- Hematopoietic Stem Cell Transplantation 2
- Multiple Myeloma Research and Treatments 2
Oncology 5
- Cancer Treatment and Pharmacology 3
- HER2/EGFR in Cancer Research 3

Co-authors: Lois Ayash (6 shared papers)E Reich (5 shared papers)Gary N. Schwartz (3 shared papers)C Lynch (3 shared papers)Anthony Elias (3 shared papers)Lowell E. Schnipper (3 shared papers)Karen H. Antman (3 shared papers)Catherine Wheeler (5 shared papers)
Journals: Journal of Clinical Oncology (5 papers)Bone Marrow Transplantation (2 papers)Leukemia (1 paper)Blood (1 paper)PubMed (1 paper)
Partner nations: United States United Kingdom

In The Last Decade

D Warren

12 papers receiving 350 citations

Peers

Countries citing papers authored by D Warren

Since Specialization

Citations

This map shows the geographic impact of D Warren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Warren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Warren more than expected).

Fields of papers citing papers by D Warren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Warren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Warren. The network helps show where D Warren may publish in the future.

Co-authors

The 25 scholars most cited alongside D Warren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D Warren Line = papers co-authored together D Warren links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work
1	Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. Journal of Clinical Oncology ·Lois Ayash, Anthony Elias, Catherine Wheeler, E Reich, Gary N. Schwartz, Rosemary Mazanet, I Tepler, D Warren, C Lynch, R Gonin	1994	117
2	Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. Journal of Clinical Oncology ·Lois Ayash, C Wheeler, Diane L. Fairclough, G Schwartz, E Reich, D Warren, Lowell E. Schnipper, Karen H. Antman, E Frei, Alby Elias	1995	99
3	High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. Journal of Clinical Oncology ·Lois Ayash, Anthony Elias, Joseph G. Ibrahim, Gary N. Schwartz, Catherine Wheeler, E Reich, C Lynch, D Warren, Charles L. Shapiro, Paul G. Richardson, David D. Hurd, Lowell E. Schnipper, Emil Frei, Karen H. Antman	1998	50
4	Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. Journal of Clinical Oncology ·Lois Ayash, Anthony Elias, Gary N. Schwartz, C Wheeler, Joseph Ibrahim, Beverly A. Teicher, E Reich, D Warren, C Lynch, Paul G. Richardson, Lowell E. Schnipper, E Frei, Karen H. Antman	1996	43
5	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia Leukemia ·Irene M. Ghobrial, Robert Redd, Philippe Armand, Ranjit Banwait, Erica N Boswell, Stacey Chuma, Daisy Huynh, Antonio Sacco, Aldo M. Roccaro, Adriana Perilla-Glen, Kimberly Noonan, Megan H. MacNabb, Houry Leblebjian, D Warren, Patrick Henrick, Jorge J. Castillo, Paul G. Richardson, J. Matous, Edie Weller, Steven P. Treon	2015	26
6	A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer Bone Marrow Transplantation ·AD Elias, Paul G. Richardson, David Avigan, Joseph G. Ibrahim, Robin Joyce, George D. Demetri, J Levine, D Warren, Timothy D. Arthur, E Reich, Catherine Wheeler, Emil Frei, Lois Ayash	2001	11
7	Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial. Blood ·Paul G. Richardson, Robert J. Soiffer, Joseph H. Antin, Zhezhen Jin, Joanne Kurtzberg, P.L. Martin, Gideon Steinbach, Karen F. Murray, G. B. Vogelsang, A. Chen, A. Krishnan, Nancy A. Kernan, David Avigan, TR Spitzer, D Warren, Carolyn Revta, Lan Wei, Massimo Iacobelli, GB McDonald, Eva C. Guinan	2006	6
8	A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies Bone Marrow Transplantation ·AD Elias, Paul G. Richardson, David Avigan, Joseph G. Ibrahim, Robin Joyce, David F. McDermott, J Levine, D Warren, Mary McCauley, Catherine Wheeler, E Frei	2001	4
9	Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. PubMed ·AD Elias, Catherine Wheeler, Lois Ayash, G Schwartz, Joseph Ibrahim, Letha E. Mills, Mary McCauley, Nicholas Coleman, D Warren, L Schnipper, K H Antman, Beverly A. Teicher, Emil Frei	1998	4
10	Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia Journal of Clinical Oncology ·Irene M. Ghobrial, J. Matouš, Swaminathan P. Iyer, A. Badros, Stacey Chuma, Renee Leduc, Meghan Rourke, Janet Kunsman, Brianna Harris, D Warren, Paul G. Richardson	2009	2
11	A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma Clinical Lymphoma & Myeloma ·AM Roccaro, Renee Leduc, Marybeth Nelson, Amy Sam, Stacey Chuma, Kristin Colson, Kelly O’Connor, IM Ghobrial, NC Munshi, R Schlossman, Brianna Harris, D Warren, AM Dollard, Jacob P. Laubach, Ravi Vij, Erica Campagnaro, Ann Birner, Virginia Dixon-Lipscomb, KC Anderson, PG Richardson	2009	1
12	A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia Clinical Lymphoma & Myeloma ·IM Ghobrial, AM Roccaro, J. Matouš, W Padmanabhan, A. Badros, R Schlossman, Stacey Chuma, Renee Leduc, Marybeth Nelson, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob D. Soumerai, D Warren, Ann Birner, NC Munshi, SP Treon, KC Anderson, PG Richardson	2009	1

About D Warren

D Warren is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Pathology and Forensic Medicine, having authored 12 papers that have together received 364 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), HER2/EGFR in Cancer Research (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Breast Cancer Treatment Studies (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Hematopoietic Stem Cell Transplantation (2 papers) and Multiple Myeloma Research and Treatments (2 papers). The work is most often cited by research in Oncology (260 citations), Hematology (105 citations), Cancer Research (138 citations), Genetics (45 citations) and Pathology and Forensic Medicine (75 citations). D Warren has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Lois Ayash, E Reich, Gary N. Schwartz, C Lynch, Anthony Elias, Lowell E. Schnipper, Karen H. Antman, Catherine Wheeler, E Frei and C Wheeler. Their work appears in journals such as Journal of Clinical Oncology, Bone Marrow Transplantation, Leukemia, Blood and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact